脂肪肝指数与受控衰减参数作为代谢功能障碍相关脂肪性肝病标志物与骨密度之间的关联:观察性研究与两样本孟德尔随机化研究
本研究利用英国生物银行与NHANES数据,观察性分析显示调整人口学因素和体重指数后代谢功能障碍相关脂肪性肝病(MAFLD)与跟骨骨密度降低显著相关,但进一步调整代谢因素后关联消失;NHANES中MAFLD与全身、股骨颈及腰椎骨密度无关,磁共振测得的肝脂肪变与骨密度无显著关联;两样本孟德尔随机化提示MAFLD和肝脂肪变对骨密度无因果效应,而超重和2型糖尿病与骨密度升高存在因果关联,腰围和高脂血症则相反。
要点
- 观察性分析中MAFLD与跟骨骨密度降低的关联在调整代谢因素后消失。
- 两样本孟德尔随机化未发现MAFLD或肝脂肪变对骨密度的因果效应。
- 超重和2型糖尿病与骨密度升高存在因果关联,腰围和高脂血症与骨密度降低相关。
核心结论
- 本研究未观察到MAFLD和肝脂肪变对骨密度有因果效应,而部分代谢因素与骨密度相关。
研究设计与样本
- 观察性分析使用英国生物银行和美国国家健康与营养调查(NHANES)数据集。
- 进行了全基因组关联分析以识别与MAFLD相关的单核苷酸多态性。
- 采用大规模两样本孟德尔随机化分析检验MAFLD、肝脂肪变或主要共病代谢因素与骨密度之间的潜在因果关联。
主要发现
- 调整人口学因素和体重指数后,逻辑回归显示MAFLD与跟骨骨密度降低显著相关。
- 进一步调整其他代谢因素后,MAFLD与跟骨骨密度降低的关联消失。
- 在NHANES数据集中,MAFLD与全身、股骨颈及腰椎骨密度无关。
- 多变量分析中,磁共振成像测得的肝脂肪变与全身、股骨颈及腰椎骨密度降低无显著关联。
- 两样本孟德尔随机化分析表明,MAFLD和肝脂肪变与骨密度无关。
关键数值与推荐
- 在所有MAFLD相关共病因素中,超重和2型糖尿病与骨密度升高存在因果关联。
- 腰围和高脂血症与骨密度降低存在因果关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Previously observational studies did not draw a clear conclusion on the association between fatty liver diseases and bone mineral density (BMD). Our large-scale studies revealed that MAFLD and hepatic steatosis had no causal effect on BMD, while some metabolic factors were correlated with BMD. The findings have important implications for the relationship between fatty liver diseases and BMD, and may help direct the clinical management of MAFLD patients who experience osteoporosis and osteopenia. PURPOSE: Liver and bone are active endocrine organs with several metabolic functions. However, the link between metabolic dysfunction-associated fatty liver disease (MAFLD) and bone mineral density (BMD) is contradictory. METHODS: Using the UK Biobank and National Health and Nutrition Examination Survey (NHANES) dataset, we investigated the association between MAFLD, steatosis, and BMD in the observational analysis. We performed genome-wide association analysis to identify single-nucleotide polymorphisms associated with MAFLD. Large-scale two-sample Mendelian randomization (TSMR) analyses examined the potential causal relationship between MAFLD, hepatic steatosis, or major comorbid metabolic factors, and BMD. RESULTS: After adjusting for demographic factors and body mass index, logistic regression analysis demonstrated a significant association between MAFLD and reduced heel BMD. However, this association disappeared after adjusting for additional metabolic factors. MAFLD was not associated with total body, femur neck, and lumbar BMD in the NHANES dataset. Magnetic resonance imaging-measured steatosis did not show significant associations with reduced total body, femur neck, and lumbar BMD in multivariate analysis. TSMR analyses indicated that MAFLD and hepatic steatosis were not associated with BMD. Among all MAFLD-related comorbid factors, overweight and type 2 diabetes showed a causal relationship with increased BMD, while waist circumference and hyperlipidemia had the opposite effect. CONCLUSION: No causal effect of MAFLD and hepatic steatosis on BMD was observed in this study, while some metabolic factors were correlated with BMD. This has important implications for understanding the relationship between fatty liver disease and BMD, which may help direct the clinical management of MAFLD patients with osteoporosis.
引用
- Zeng L, Li Y, Hong C, et al. Association between fatty liver index and controlled attenuation parameters as markers of metabolic dysfunction-associated fatty liver disease and bone mineral density: observational and two-sample Mendelian randomization studies. Osteoporos Int. 2024. PMID: 38221591. doi:10.1007/s00198-023-06996-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。